Advertisement

Topics

Uveitis - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Uveitis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 159-page report is available in PDF from $2000.

Uveitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Uveitis - Pipeline Review, H1 2015’, provides an overview of the Uveitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Uveitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Uveitis Overview 11
Therapeutics Development 12
Pipeline Products for Uveitis - Overview 12
Pipeline Products for Uveitis - Comparative Analysis 13
Uveitis - Therapeutics under Development by Companies 14
Uveitis - Therapeutics under Investigation by Universities/Institutes 18
Uveitis - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Uveitis - Products under Development by Companies 22
Uveitis - Products under Investigation by Universities/Institutes 26
Uveitis - Companies Involved in Therapeutics Development 27
AbbVie Inc. 27
Aciont Inc. 28
Apitope International NV 29
BBB Therapeutics B.V. 30
Can-Fite BioPharma Ltd. 31
Clearside BioMedical, Inc. 32
Effimune SAS 33
Eleven Biotherapeutics Inc. 34
Endocyte, Inc. 35
Enzo Biochem, Inc. 36
EyeGate Pharmaceuticals, Inc. 37
ForSight VISION4, Inc. 38
HanAll Biopharma Co., Ltd. 39
Icon Bioscience, Inc. 40
IMMD Inc. 41
Johnson & Johnson 42
Neuroptis Biotech 43
Novartis AG 44
Ocata Therapeutics, Inc. 45
OncoNOx ApS 46
Panoptes Pharma Ges.m.b.H. 47
Pfizer Inc. 48
pSivida Corp. 49
Regeneron Pharmaceuticals, Inc. 50
Santen Pharmaceutical Co., Ltd. 51
SynDevRx, Inc. 52
TxCell SA 53
Virogenomics, Inc. 54
XOMA Corporation 55
Uveitis - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
2B3-201 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
adalimumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ATXUV-1 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ATXUV-2 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
B27-PD - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
celecoxib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CF-101 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Col-Treg - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Cytectin - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
dexamethasone acetate - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Dexamethasone Sodium Phosphate-Visulex - Drug Profile 81
Product Description 81
Mechanism of…

For more information open Uveitis - Pipeline Review, H1 2015.

SKU: GMDHC6260IDB

Original Article: Uveitis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Uveitis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...